Selegiline transdermal system (STS) as an aid for smoking cessation

Roberta Kahn, Liza Gorgon, Karen Jones, Frances McSherry, Elbert D. Glover, Robert M. Anthenelli, Thomas Jackson, Jill Williams, Cristin Murtaugh, Ivan Montoya, Elmer Yu, Ahmed Elkashef

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: This study examined the efficacy and safety of selegiline transdermal system (STS) and brief repeated behavioral intervention (BRBI) for smoking cessation in heavy smokers. We hypothesized that the quit rate of subjects who received STS and BRBI would be significantly greater than that of those who received placebo patch and BRBI. Methods: This was a double-blind, placebo-controlled parallelgroup study in which 246 men and women were randomized to receive either STS (n = 121) or placebo patch (n =125) for 9 weeks. Recruitment targeted heavy smokers, defined as individuals with self-reported use of ≥15 cigarettes/day in the 30 days prior to enrollment, who had smoked cigarettes for the past 5 years, and had an expired CO level ≥9 ppm during screening. Results: Although STS was well tolerated, the overall results indicated that STS with BRBI was not more effective than placebo plus BRBI for smoking cessation (p = .58). Conclusions: The results are discussed in relation to interventions for heavy smokers. Although 2 trials using oral selegiline both showed trends toward improved abstinence, these results indicate that STS with BRBI was not an effective aid for smoking cessation at the end of treatment (10 weeks), 14, or 26 weeks. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco 2011.

Original languageEnglish (US)
Pages (from-to)377-382
Number of pages6
JournalNicotine and Tobacco Research
Volume14
Issue number3
DOIs
StatePublished - Mar 6 2012

Fingerprint

Selegiline
Smoking Cessation
Placebos
Tobacco Products
Carbon Monoxide
Safety

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

Kahn, R., Gorgon, L., Jones, K., McSherry, F., Glover, E. D., Anthenelli, R. M., ... Elkashef, A. (2012). Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine and Tobacco Research, 14(3), 377-382. https://doi.org/10.1093/ntr/ntr143
Kahn, Roberta ; Gorgon, Liza ; Jones, Karen ; McSherry, Frances ; Glover, Elbert D. ; Anthenelli, Robert M. ; Jackson, Thomas ; Williams, Jill ; Murtaugh, Cristin ; Montoya, Ivan ; Yu, Elmer ; Elkashef, Ahmed. / Selegiline transdermal system (STS) as an aid for smoking cessation. In: Nicotine and Tobacco Research. 2012 ; Vol. 14, No. 3. pp. 377-382.
@article{ba64b2c38ae14facb11e13009ca7d406,
title = "Selegiline transdermal system (STS) as an aid for smoking cessation",
abstract = "Introduction: This study examined the efficacy and safety of selegiline transdermal system (STS) and brief repeated behavioral intervention (BRBI) for smoking cessation in heavy smokers. We hypothesized that the quit rate of subjects who received STS and BRBI would be significantly greater than that of those who received placebo patch and BRBI. Methods: This was a double-blind, placebo-controlled parallelgroup study in which 246 men and women were randomized to receive either STS (n = 121) or placebo patch (n =125) for 9 weeks. Recruitment targeted heavy smokers, defined as individuals with self-reported use of ≥15 cigarettes/day in the 30 days prior to enrollment, who had smoked cigarettes for the past 5 years, and had an expired CO level ≥9 ppm during screening. Results: Although STS was well tolerated, the overall results indicated that STS with BRBI was not more effective than placebo plus BRBI for smoking cessation (p = .58). Conclusions: The results are discussed in relation to interventions for heavy smokers. Although 2 trials using oral selegiline both showed trends toward improved abstinence, these results indicate that STS with BRBI was not an effective aid for smoking cessation at the end of treatment (10 weeks), 14, or 26 weeks. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco 2011.",
author = "Roberta Kahn and Liza Gorgon and Karen Jones and Frances McSherry and Glover, {Elbert D.} and Anthenelli, {Robert M.} and Thomas Jackson and Jill Williams and Cristin Murtaugh and Ivan Montoya and Elmer Yu and Ahmed Elkashef",
year = "2012",
month = "3",
day = "6",
doi = "https://doi.org/10.1093/ntr/ntr143",
language = "English (US)",
volume = "14",
pages = "377--382",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "3",

}

Kahn, R, Gorgon, L, Jones, K, McSherry, F, Glover, ED, Anthenelli, RM, Jackson, T, Williams, J, Murtaugh, C, Montoya, I, Yu, E & Elkashef, A 2012, 'Selegiline transdermal system (STS) as an aid for smoking cessation', Nicotine and Tobacco Research, vol. 14, no. 3, pp. 377-382. https://doi.org/10.1093/ntr/ntr143

Selegiline transdermal system (STS) as an aid for smoking cessation. / Kahn, Roberta; Gorgon, Liza; Jones, Karen; McSherry, Frances; Glover, Elbert D.; Anthenelli, Robert M.; Jackson, Thomas; Williams, Jill; Murtaugh, Cristin; Montoya, Ivan; Yu, Elmer; Elkashef, Ahmed.

In: Nicotine and Tobacco Research, Vol. 14, No. 3, 06.03.2012, p. 377-382.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Selegiline transdermal system (STS) as an aid for smoking cessation

AU - Kahn, Roberta

AU - Gorgon, Liza

AU - Jones, Karen

AU - McSherry, Frances

AU - Glover, Elbert D.

AU - Anthenelli, Robert M.

AU - Jackson, Thomas

AU - Williams, Jill

AU - Murtaugh, Cristin

AU - Montoya, Ivan

AU - Yu, Elmer

AU - Elkashef, Ahmed

PY - 2012/3/6

Y1 - 2012/3/6

N2 - Introduction: This study examined the efficacy and safety of selegiline transdermal system (STS) and brief repeated behavioral intervention (BRBI) for smoking cessation in heavy smokers. We hypothesized that the quit rate of subjects who received STS and BRBI would be significantly greater than that of those who received placebo patch and BRBI. Methods: This was a double-blind, placebo-controlled parallelgroup study in which 246 men and women were randomized to receive either STS (n = 121) or placebo patch (n =125) for 9 weeks. Recruitment targeted heavy smokers, defined as individuals with self-reported use of ≥15 cigarettes/day in the 30 days prior to enrollment, who had smoked cigarettes for the past 5 years, and had an expired CO level ≥9 ppm during screening. Results: Although STS was well tolerated, the overall results indicated that STS with BRBI was not more effective than placebo plus BRBI for smoking cessation (p = .58). Conclusions: The results are discussed in relation to interventions for heavy smokers. Although 2 trials using oral selegiline both showed trends toward improved abstinence, these results indicate that STS with BRBI was not an effective aid for smoking cessation at the end of treatment (10 weeks), 14, or 26 weeks. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco 2011.

AB - Introduction: This study examined the efficacy and safety of selegiline transdermal system (STS) and brief repeated behavioral intervention (BRBI) for smoking cessation in heavy smokers. We hypothesized that the quit rate of subjects who received STS and BRBI would be significantly greater than that of those who received placebo patch and BRBI. Methods: This was a double-blind, placebo-controlled parallelgroup study in which 246 men and women were randomized to receive either STS (n = 121) or placebo patch (n =125) for 9 weeks. Recruitment targeted heavy smokers, defined as individuals with self-reported use of ≥15 cigarettes/day in the 30 days prior to enrollment, who had smoked cigarettes for the past 5 years, and had an expired CO level ≥9 ppm during screening. Results: Although STS was well tolerated, the overall results indicated that STS with BRBI was not more effective than placebo plus BRBI for smoking cessation (p = .58). Conclusions: The results are discussed in relation to interventions for heavy smokers. Although 2 trials using oral selegiline both showed trends toward improved abstinence, these results indicate that STS with BRBI was not an effective aid for smoking cessation at the end of treatment (10 weeks), 14, or 26 weeks. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco 2011.

UR - http://www.scopus.com/inward/record.url?scp=84863229239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863229239&partnerID=8YFLogxK

U2 - https://doi.org/10.1093/ntr/ntr143

DO - https://doi.org/10.1093/ntr/ntr143

M3 - Article

C2 - 21846661

VL - 14

SP - 377

EP - 382

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 3

ER -

Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, Anthenelli RM et al. Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine and Tobacco Research. 2012 Mar 6;14(3):377-382. https://doi.org/10.1093/ntr/ntr143